TSikloferon injectable solution 12.5% ​​2ml amp piece 5

Description

Composition
Active substance:
1 ml of solution contains: meglumine akridonatsetat in terms of akridonuksusnuyu acid 125.0 mg prepared according to the following recipe: akridonuksusnaya acid, 125.0 mg, N-methylglucamine (meglumine) 96.3 mg.
Excipients:
Water for injection to 1.0 ml.
Description:
Transparent yellow liquid.
Product form:
Solution for intravenous and intramuscular administration of 125 mg / ml in 2 ml ampoules of colorless or brown glass. Per vial affixed adhesive label. 5 ampoules in blisters of PVC film. Blisters heat-sealed with a film or coating of aluminum foil or open. 1 blisters together with instructions for use in a stack of cardboard.
Contraindications
Pregnancy, lactation, increased sensitivity to the drug, decompensated cirrhosis, children up to 4 years.
Dosage
12,5%
Indications
In adults in the treatment: – of HIV infection (stages 2A – 2B); – CNS: serous meningitis and encephalitis, tick-borne borellioz (Lyme disease); – viral hepatitis A, B, C, D; – herpes and cytomegalovirus infection; – secondary immunodeficiency associated with acute and chronic bacterial and fungal infections; – chlamydial infections; – systemic rheumatic and connective tissue diseases (rheumatoid arthritis, systemic lupus erythematosus); – degenerative joint diseases: osteoarthritis deformans and others.
The children in the treatment of: – viral hepatitis A, B, C, D; – herpes infection; – HIV infection (stages 2A – 2B).
Interaction with other drugs
TSikloferon and compatible blends well with all drugs traditionally used in the treatment of these diseases (interferons, chemotherapeutic drugs, etc.).
It enhances the action of interferons and nucleoside analogues. It reduces the side effects of chemotherapy, interferon.
Overdose
Data on overdose of the drug available.
pharmachologic effect
Pharmacological group:
Immunostimulatory agent.
Pharmacodynamics:
Cycloferon is a low molecular interferon inducer, which defines a wide range of its biological activity (antiviral, immunomodulatory, anti-inflammatory and others.).
The major producer cells when interferon administration Cyclopheron are macrophages, T- and B-lymphocytes. Depending on the type of infection occurs predominance of a particular activity mediated immunity. The drug induces high titers of interferon in tissues and organs containing lymphoid elements (spleen, liver, lungs), activates stem cells in bone marrow, stimulating the formation of granulocytes. Tsikloferon activates T lymphocytes and natural killer cells, normalizes the balance between subpopulations of T-helper and T-suppressor. It enhances the activity of alpha-interferon.
Tsikloferon effective against viruses of tick-borne encephalitis, influenza, hepatitis, herpes, cytomegalovirus, human immunodeficiency virus, papilloma virus and other viruses. In acute viral hepatitis TSikloferon prevents the transition of diseases into a chronic form.
In step primary manifestations of HIV infection helps stabilize the performance of immunity.
The high efficiency of the drug in the treatment of acute and chronic bacterial infections (CNS, chlamydia, bronchitis, pneumonia, postoperative complications, urogenital infection, peptic ulcer disease) as a component of immunotherapy.
TSikloferon exhibits high efficiency in rheumatic and systemic connective tissue diseases by suppressing autoimmune responses, and providing anti-inflammatory and analgesic effect.
Pharmacokinetics:
When administered the maximum tolerated dose maximum concentration achieved within 1-2 hours, after 24 hours the drug in the blood is detected in trace amounts. It overcomes the blood-brain barrier. The half-life is 4-5 hours. Not accumulates in the body for prolonged use.
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions.
If any of the undesirable effects mentioned in the instructions are compounded or you notice any other unwanted effects not mentioned in the instructions, tell your doctor.
special instructions
TSikloferon not affect the ability to drive. In diseases of the thyroid gland should consult endocrinologist. staining of urine is possible in violet-blue (luminescence).
Storage conditions
In the dark place at a temperature of from 0 to 25 C. The freezing of the solution during transportation at low temperatures does not change the properties of the drug. Thawed at room temperature, the drug maintains its biological and physico-chemical properties. When changing the color of the solution and formation of sludge using the product unacceptable.
Keep out of the reach of children.
Dosing and Administration
In adults:
Tsikloferon used intramuscularly or intravenously once a day to the standard regimen: one day. The duration of treatment depends on the disease.
1. Herpes and Cytomegalovirus infection drug is administered to the standard regimen of 10 injections total dose of 0.25 g of 2,5 treatment is most effective early in disease aggravation.
2. When neuroinfections preparation is administered to the standard regimen. The treatment of 12 injections of 0.25-0.5 g in combination with a causal therapy. The total dose of 3-6 Repeated courses are held as needed.
3. chlamydial infection drug is administered to the standard regimen. The treatment of 10 injections of 0.25, the total dose is 2.5 g Repeated treatment is carried out after 10-14 days. Advantageously Cyclopheron combination with antibiotics.
4. In acute viral hepatitis A, B, C, D and mixed forms of medication administered to the standard regimen of 10 injections total dose of 0.5 5.0 g When protracted course of the infection rate is repeated after 10-14 days.
In chronic viral hepatitis B, C, D and mixed forms of medication administered to the standard regimen of 10 injections of 0.5 g, then the maintenance dose, 3 times a week for three months in the complex therapy. It is recommended in combination with interferon and chemotherapy. Repeat the course of 10-14 days.
5. HIV infection (stages 2A – 2B) the drug administered to the standard regimen of 10 injections of 0.5 g and then the maintenance dose once every three days for 2.5 months. Repeat the course of 10 days.
6. When immunodeficient states treatment 10 intramuscular injections of the standard regimen in a single dose, the total dose of 0.25 2.5 g Repeated courses 6-12 months.
7. In systemic rheumatic and connective tissue diseases 4 courses of 5 injections of 0.25 g of the standard regimen, with an interval of 10-14 days. Repeated courses of doctor’s recommendation.
8. In degenerative diseases of the joints 2 courses of 5 injections of 0.25 g of the standard regimen, with an interval of 10-14 days. Repeated courses of doctor’s recommendation.
In children:
In pediatric practice TSikloferon used intramuscularly or intravenously once a day to the standard regimen: one day. The daily therapeutic dose is 6-10 mg / kg body weight.
1. In acute viral hepatitis A, B, C, D and mixed forms of medication administered to the standard regimen of 15 injections.
When protracted course of repeated infection rate of 10-14 days.
2. In chronic viral hepatitis B, C, D preparation is administered by injection core circuit 10 and then the maintenance dose three times per week for three months in the complex therapy. It is recommended in combination with interferon and chemotherapy.
3. HIV infection (stages 2A – 2B) injection rate of 10 to the standard regimen and further the maintenance dose once every three days for three months. Repeated courses are held in 10 days.
4. HSV infection rate of 10 injections of the standard regimen. When you save a replicative virus activity continue treatment with the maintenance dose administration every three days for four weeks.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist